The effect of sympathetic stimulation on bronchial smooth muscle contractile response after mast cell degranulation with Ascaris suum antigen was studied in 36 natively allergic dogs in situ. Bronchial smooth muscle response was measured isometrically in a single right middle lobe bronchus. A dose of antigen causing maximal release of mediator was administered to the bronchus through the bronchial arterial circulation. Serial plasma histamine concentrations were determined at 15-s intervals after intra-arterial (i.a.) administration of antigen. Samples of blood were obtained simultaneously from right heart and femoral artery, and arteriovenous difference (AVd) in histamine concentration across the bronchus was determined during mast cell degranulation. In nine dogs showing bronchial mast cell degranulation to antigen challenge, bronchial smooth muscle contraction was 22.3±2.95 g and the mean AVd in histamine concentration across the bronchus was 188±41.5 ng/ml. Six other dogs having muscarinic blockade with 0.75-1.0 mg/kg intravenous atropine were given i.a. antigen after 1 min of steady-state sympathetic stimulation with intravenous 1,1-dimethyl4-phenylpiperazinium iodide (DMPP). Sympathetic stimulation during Ascaris suum antigen challenge caused complete inhibition of bronchial smooth muscle contractile response to i.a. antigen (P < 0.001), and a significant AVd in histamine concentration across the bronchus (9.8±16.0 ng/ml; P < 0.01 vs. control) was not detected. Peak plasma histamine concentration in control dogs was 1,138±237 ng/ml vs. 310±135 ng/ml in animals receiving sympathetic stimulation (P < 0.01). In four dogs undergoing systemic anaphylaxis to i.v. antigen, subsequent sympathetic stimulation with i.v. DMPP reduced bronchomotor tone to '70% of base-line control. Exogenously induced sympathetic stimulation can substantially inhibit systemic mast cell degranulation to Ascaris suum antigen in allergic dogs. Maximal stimulation of the sympathetic nervous Preliminary reports of this work were presented at the annual meeting of the
Introduction
The sympathetic nervous system plays a potentially important role in the regulation of respiratory mast cell secretion (1) (2) (3) and bronchomotor response (4) (5) (6) (7) . Orange and co-workers (1) have shown that beta-adrenergic stimulation inhibited degranulation of mast cells in passively sensitized human lung strips. Brown et al. (4) have shown that beta-adrenergic stimulation of canine tracheal smooth muscle in situ partially or completely inhibited mast cell degranulation. However, mast cell degranulation was achieved by a nonimmune mechanism employing Compound 48/80 in these studies (4) ; immune degranulation could not be achieved in tracheal airways in situ. Barnett and co-workers (8) showed inhibition of mast cell degranulation to Ascaris suum antigen in peripheral airways by intravenous (i.v.) administration of isoproterenol in natively allergic dogs. However, in all prior studies, the pharmacological doses of isoproterenol required were substantial, and the potential for physiological inhibition of mast cell degranulation could not be assessed. Leff and co-workers (6, 7) have shown that neural sympathetic stimulation of tracheal smooth muscle in situ antagonized respiratory smooth muscle contraction caused by intra-arterially (i.a.)' administered histamine. These studies used exogenous histamine, and inhibition of smooth muscle contraction caused by the immune degranulation process could not be assessed.
A potential limitation to prior in situ studies of mast cell or respiratory smooth muscle response in central airways has been the use of trachea as a representative resistance airway (4) (5) (6) (7) . Recent reports (9, 10) have shown that the density of innervation and postsynaptic respiratory receptors in trachea differ substantially from the bronchial airways in which asthmatic bronchoconstriction occurs. Furthermore, the density of respiratory mast cells increases substantially from the trachea to the peripheral airways (11). Inhibition of tracheal smooth muscle response to mast cell degranulation, therefore, might not reflect the response in bronchial airways, which have a greater density of respiratory mast cells (11) and HI-receptors (12) .
The objective of this study was to determine the potential 1 . Abbreviations used in this paper: AA, Ascaris suum antigen; ACh, acetylcholine chloride; AF, active force; AVd, arteriovenous difference across the bronchus; DMPP, 1, l-dimethyl-4-phenylpiperazinium iodide;
[H], histamine concentration; i.a., intra-arterial; MAP, mean arterial blood pressure; Paw, lateral airway pressure; PtP, transpulmonary pressure.
inhibitory effects of physiological sympathetic stimulation on (a) respiratory and systemic mast cell secretion of mediator, and (b) respiratory smooth muscle response during immune degranulation in the bronchial airways of a living animal. To assess the importance of endogenous sympathetic stimulation in these systems, we used a method for selective perfusion and measurement of the smooth muscle contractile response of a single third order canine bronchus in situ (5) . This preparation permits sequential, simultaneous analysis of the physiological and biochemical events of mast cell degranulation in a relevant resistance bronchus of the lung. In this study, we evaluated the effect of steady-state sympathetic stimulation on mast cell secretion of histamine and canine bronchial smooth muscle response in situ. We show for the first time that physiological sympathetic reserve is sufficient to substantially inhibit the consequences of mast cell degranulation in a major resistance airway. (Fig. I) ; a catheter also was placed at the pulmonary outflow tract of the right heart through an incision into the right ventricle and secured by a purse-string suture. Another catheter was inserted through the right internal jugular vein or caudal vena cava to a position just proximal to the azygos inflow to the superior vena cava (Fig. 1 ).
Methods
Bronchial smooth muscle response was measured in a 1-cm segment of right middle lobe bronchus. Details of this preparation have been described previously (5) . Thoracotomy was performed into the right fifth intercostal space. The common bronchoesophageal artery was located and cannulated with PE50 (0.58 mm internal diam) tubing. The left bronchoesophageal artery, branches to the upper and lower lobes, and any muscular branches identified, were ligated, so that i.a. injection selectively perfused the bronchus ( Fig. 1) (5) . After cannulation, the bronchial segment was fixed for isometric measurement of bronchial smooth muscle response (5) . The 1-cm bronchial segment was tethered between sutures attached on one side to a parallel bar and on the other to a force displacement transducer (Model FT.03; Grass Instrument Co., Quincy, MA) mounted on a rack and pinion (Fig. 1) . The sutures were oriented at 1800, and bronchial resting force was preset to 35-40 g. This corresponded to a transverse length of 0.8 cm at which active force (AF) has been shown to be >95% of the maximum achievable response. Bronchial smooth muscle contractile response was assessed by subtracting the force achieved after administration of agonist or antigen from the initial resting force to give AF. Active Figure 1 . Schema of preparation. Top, third order bronchus is fixed isometrically; bronchoesophageal artery catheter permits selective delivery of antigen to bronchial airway. Isometrically fixed tracheal segment serves as control airway. Bottom, sites for withdrawal of blood samples during mast cell degranulation. bronchial smooth muscle tension was thus expressed as grams force (g).
To assess the specificity of bronchial response in these studies, the response of a 2.6-3.8-cm segment of trachea was used as a control airway (5). The tracheal segment was fixed for isometric measurement in a manner similar to the bronchus (4, 6) . Tracheal smooth muscle response was assessed as for bronchus. Active force was expressed as grams force and was normalized by dividing by the axial length of the tracheal segment, so that tracheal active force also was expressed for a 1-cm segment of tracheal airway (grams per centimeter).
Physiological measurements were monitored continuously on a polygraph (Model 7D; Grass Instrument Co.). Arterial blood pressure was measured through a 1.67-mm internal diameter catheter (PE 240) inserted into the abdominal aorta through the remaining femoral artery. Lateral airway pressure (Paw) was measured using a PM 5E±0.7 differential air pressure transducer (Gould, Inc., Santa Clara, CA) that was referenced to atmosphere. All animals had bilateral thoracotomy so that Paw was equal to transpulmonary pressure (PtP). PtP was maintained at 5 cm H20 after thoracotomy to avoid atelectasis. All (5, 10, 13) . This preliminary assessment of the adequacy of the preparation was performed initially in all control and sympathetically stimulated animals (see below). These data also were compared with the response obtained after i.a. and i.v. Ascaris suum antigen extract (see below).
In six separate dogs, the dose of Ascaris antigen extract causing maximal bronchial contraction was assessed. 45 min after i.a. ACh, sham injection of Krebs-Henseleit diluent was administered i.a. into the bronchial circulation. After showing no response to the diluent in which the antigen was dissolved, 3 ml of Ascaris antigen extract was injected i.a. into the bronchial artery at 90-s intervals in increasing concentrations. An initial 3-ml dose of 1:100 was followed by 1:30 and 1:10 dilutions. A second 3-ml injection of 1:10 dilution of Ascaris antigen extract was given 90 s later as the final dose.
Samples of blood were obtained simultaneously for histamine assay from the right atrial orifice, right ventricle, and femoral artery ( Fig. 1 (4, 9, 13) . Although the AVd in plasma [H] does not measure the absolute amount of histamine secreted from the bronchial airway, these preliminary studies have shown a direct correlation between the magnitude of the AVd and airway contraction. The physiological and biochemical responses from these studies were used to determine a single dose of antigen causing maximal release of mediator from the bronchus from i.a. antigen injection. This concentration was used in subsequent studies (see below).
To further assess the sequence and magnitude of airway and cardiovascular effects of systemic analphylaxis caused by Ascaris antigen, Ascaris antigen extract was administered i.v. in seven additional dogs. Animals were prepared identically as above, except that placebo injection was administered i.v. through the femoral venous catheter in 5.0 ml isotonic saline buffered to pH 7. Plasma histamine assay. 5-ml samples of blood for histamine assay were drawn in disposable syringes coated with heparin. These were transferred immediately after each experiment and centrifugated at 40C (at 1,300 g) for 10 min. The plasma supernatant for each sample was immediately frozen at -40C. Samples were coded and assayed in single blind manner, so that the nature of each experiment was not known during assay. Histamine assay was performed by enzymatic isotope assay according to the methods of Beaven et al. (18) and Snyder et al. (19) . We previously reported the details and validation techniques for this assay (4, 9) for respiratory histamine analysis. For the present studies, the sensitivity of the assay was determined from control samples containing known concentrations of histamine. Samples containing 0.55 ng/ml (5 pmol/ml) were statistically discernible from blank control samples (P < 0.01). Plasma samples were assayed in dilutions ranging from 1.0 to 55.0 ng/ml. The coefficients of variation determined from control samples over these ranges were 0.179 (I ng/ ml), 0.157 (I 1.0 ng/ml), and 0.140 (55 ng/ml).
Statistical (Fig.  2) . In subsequent studies, this dose (3 ml i.a. of 1:10 dilution) was considered to be the single dose of antigen extract approximating the maximal physiological and mast cell degranulating 2. Although tracheal and bronchial contraction are approximately equal, the force of bronchial contraction is .70% maximal (5); force of tracheal contraction is only about 25% maximal (4, 5, 10) . This is due to the substantially greater muscle mass of the trachea. (Fig. 4) . Tracheal contractile force in the same nine animals was 11.3±3.44 was demonstrated corresponding to onset of bronchial contraction in these same dogs (Fig. 4, Table I ).
Five animals (see above) demonstrated either no response to i.a. antigen (n = 2) or delayed onset of bronchial contraction that occurred simultaneously with tracheal contraction (n = 3). These animals were considered to be nonresponders and were excluded from the data pool (Table I) DMPP caused increase in MAP to 66±8.2% of control value before antigen challenge (P < 0.001). Bronchial AF decreased by 67±12% to 15.7±5.8 g (P < 0.001) and tracheal AF by 83.5±8.5% to 5.8±3.0 g/cm (P < 0.001). These values were sustained for the 2 min of DMPP infusion. 
Discussion
This report is the first demonstration that the in situ reserve of the sympathetic nervous system is sufficient to potentially inhibit the consequences of immune degranulation in the bronchial airways of dogs. The effects on antigenic challenge in bronchial airways and during systemic anaphylaxis were studied during and after maximal exogenously induced sympathetic stimulation. These data show (a) that substantial but not complete inhibition of antigen-induced degranulation of mast cells and basophiles can be elicited during sympathetic stimulation, (b) abolition of the arteriovenous difference in [H] across the bronchus during maximal sympathetic stimulation, implying even greater inhibition of the airway (vs. systemic) degranulation response, and (c) complete inhibition of the airway contractile response to regionally secreted and circulating mediator during sympathetic stimulation. Note that these data assess the potential physiological reserve of sympathetic nervous system, and do not define the circumstances under which a homeostatic bronchodilator response is elicited. These data also do not define the extent to which the sympathetic secretory reserve can be recruited during immune challenge.
Also consider the implications of these findings in terms of the model employed. Antigen challenge was administered to natively allergic mongrel dogs. These animals have been shown previously to have no intrinsic airway hyperreactivity (14, 21) . It also is presumed that histamine secretion caused by Ascaris antigen in these studies resulted from immune (IgEmediated) degranulation. A linear relationship between concentrations of Ascaris antigen (1:100 to 1:10) and force of bronchial contraction was obtained (Fig. 2 ). Although it is not possible to exclude nonspecific degranulation of respiratory mast cells at the highest concentration of antigen, the onset of immune degranulation occurred substantially later (-30 s) and magnitude of histamine secretion was about twofold that which we have observed during nonimmune degranulation using this identical model (13) . In two animals showing no physiological response to Ascaris antigen, no respiratory circulating histamine was detected (Table I) .
Some canine strains do show nonspecific airway hyperreactivity (21) . It also is possible to induce immune sensitization in dogs to specific antigen. However, the objective of this study was to determine the potential regulatory mechanisms modulating bronchoconstriction in atopic dogs that were not overtly asthmatic (21) . Therefore, in this canine model, we chose to exclude canine strains with either endogenous airway hyperreactivity (21) or nonenvironmentally acquired allergy.
Because natively allergic dogs do not always manifest respiratory immune hypersensitivity (6, 7, (13) (14) (15) , it was essential to establish criteria for assessing immune degranulation after antigen challenge. Studies were performed to show that the dose of antigen administered i.a. caused (a) maximal regional secretion of mediator (histamine) and (b) maximal physiological response in the airway (isometric bronchial contraction). This was the dose of antigen used in antigen challenge studies (Fig. 2) . Because antigen was administered i.a. directly into the circulation of a major resistance bronchus, precise timing of the events of immune degranulation was possible (Tables I and II, Figs. 3 and 4) (13) . By showing contraction in the bronchus that preceded contraction in a control (tracheal) airway in the same animal (Fig. 3) , it was possible to distinguish 2044 Garrity et al. .3to %,onxroi dogs having specific bronchial reactivity to i.a. administration of antigen. These results differed substantially from the response obtained with i.v. administration of antigen (Fig. 3) , where antigen presumably was distributed simultaneously to tracheal and bronchial airways through the systemic circulation after intravenous injection. By demonstrating contraction of the bronchus that preceded contraction in a control (tracheal) airway ( Figs. 3 and 5 ; Tables I and II) , it was possible to distinguish dogs manifesting respiratory reactivity. Where equivalent quantities of agonist are administered, tracheal contraction always substantially exceeds bronchial contraction due to the greater muscle mass in the trachea (5). In these studies, i.a. injection of antigen caused substantially greater contraction in bronchus relative to the trachea (Fig. 3 , Table  I ). An arteriovenous difference in [H] across the bronchus also was shown, and bronchial contraction preceded tracheal contraction in all animals reacting to i.a. injection of Ascaris antigen. In contrast, animals considered to be nonreactive showed none of these characteristics (Table I) (13) . Use of the selective bronchial preparation in this study thus permitted: (a) precise timing of the response essential for assessing specificity of mast cell degranulation, (b) measurement of the response of a specific resistance bronchus analogous to that involved in asthmatic bronchoconstriction, and (c) estimation of the magnitude of the mast cell response in this (bronchial) airway during antigen challenge.
In dogs demonstrating regional airway reactivity to i.a. antigen extract, contraction of the control (tracheal) airway was observed (Fig. 3, Table I ). Tracheal contraction, which had an onset equal to approximately one circulation time (Tables I and II) , resulted either from washout of mediator from the bronchial circulation or from recirculation of antigen extract to the tracheal airway. It is less likely, however, that recirculating antigen caused degranulation of respiratory mast cells and/or basophiles in canine trachea. In preliminary studies, we and others (4, 9) were unable to show histamine secretion in the trachea in natively allergic dogs when intraarterial Ascaris antigen extract was injected directly into the tracheal arterial circulation. However, completely selective mast cell degranulation (right middle lobe bronchus only) is not an essential requirement of this study, since endogenous sympathetic stimulation caused substantial inhibition (Table  II) or substantial reversal of respiratory smooth muscle contraction (Fig. 5) for the duration of sympathetic stimulation.
Although this model does not permit specific assessment of the late events of immune degranulation, there are several potential advantages to the use of the preparation in these studies. By administering antigen i.a. directly into a third order bronchus, we were able to assess directly the early events of asthmatic bronchoconstriction in a major resistance bronchus of the lung, an airway that is predominant in the bronchoconstrictor response. This is especially important, since it recently has been shown that the physiological (5) and pharmacological (10) properties of bronchial smooth muscle differ substantially from tracheal smooth muscle or from smooth muscle in peripheral airways (12) . The technique (rapid i.a. injection) used in this study also permitted precise timing of the events of immune degranulation, which is not possible with aerosol inhalation of antigen (14, 15, 22) . L.a. administration of antigen directly into the bronchial airway permitted precise correlation between the physiological response and the events of immune degranulation. In these studies, immune degranulation was correlated to regional concentration in plasma histamine. This does not exclude the importance of other mediators ofimmune degranulation, e.g., slow reacting substance. However, preliminary studies indicate a minor role of leukotrienes in the early events of immune degranulation in natively allergic mongrel dogs (13) .
To determine the potential role of the sympathetic nervous system in preventing immune degranulation in normal (nonhyperreactive [21] ) natively allergic dogs, we used a dose of antigen that caused maximal regional bronchial contraction (Fig. 2) and a level of sympathetic stimulation shown in previous studies (6, 7) to approximate 100% of the sympathetic reserve. Infusion of DMPP permitted steady-state stimulation of all sympathetic ganglia (6, 7) and hence simultaneous stimulation of both adrenal secretion and sympathetic nervous innervation of the airways. This was essential, since we have shown previously that adrenal secretion is the predominant mechanism by which the sympathetic nervous system antagonized bronchoconstrictor stimuli (7) . Studies have shown that pharmacological beta-adrenergic stimulation may prevent the effects of immune degranulation in vitro (3) and nonimmune degranulation in vivo (4) . This has led to the theoretical assumption that sufficient beta-adrenergic stimulation might inhibit the airway smooth muscle contractile response to mediator (23) or the secretion of mediator (24) from respiratory mast cells. It has been assumed, however, that the degree of sympathetic stimulation required to prevent mast cell degranulation from immune challenge could not be accomplished physiologicqlly, since the level of stimulation required to inhibit mast cell degranulation was approximately tenfold greater than that required to prevent bronchial smooth muscle contraction to secreted mediator (25) .
In this report, we show for the first time that sufficient physiological reserve exists to prevent both respiratory mast cell secretion of histamine and respiratory smooth muscle contraction to secreted mediator. All animals receiving 1-2 min of sympathetic stimulation before administration of antigen showed subsequent reactivity to histamine. The dose of antigen administered caused maximal secretion of histamine from bronchial airways (Fig. 2) (Fig. 5 ). These studies also were performed under conditions of maximal sympathetic stimulation and maximal antigenic degranulation. These data show the potential of the sympathetic nervous system to reverse substantially the effects of antigenic stimulation on airway smooth muscle response. However, these data do not define the homeostatic role of the sympathetic nervous system in regulating bronchomotor tone. During anaphylaxis, the spontaneous sympathetic response shown in these studies was not enough to restore completely arterial blood pressure or bronchomotor tone to base-line prechallenge levels (Tables I and  II) . These data indicate that, although substantial sympathetic reserve exists to inhibit both mediator secretion and bronchomotor response, the extent to which this reserve is used and the physiological factors evoking sympathetic activation during antigen challenge remain incompletely defined. We conclude that prior in vitro studies demonstrating inhibition of the mast cell degranulating response after betaadrenergic stimulation are of potential physiological importance in vivo. Our data show that sufficient sympathetic reserve exists in atopic dogs to substantially inhibit immune degranulation of bronchial mast cells. The precise physiological homeostatic role of the sympathetic nervous system in regulating mediator secretion and bronchomotor response remains to be defined.
